Phase I safety study of 0.5% PRO 2000 vaginal Gel among HIV un-infected women in Pune, India

Por Smita, Joshi, Soma, Dutta, Beverly, Bell, Albert, Profy, JoAnn, Kuruc, Fang, Gai, Missy, Cianciola, Lydia, Soto-Torres, Anjali, Panchanadikar, Arun, Risbud, Sanjay, Mehendale, Steven J, Reynolds
Publicado em 2006

Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.

Por Marla J Keller, Pedro M M Mesquita, N Merna Torres, Sylvia Cho, Gail Shust, Rebecca P Madan, Hillel W Cohen, Julie Petrie, Tara Ford, Lydia Soto-Torres, Albert T Profy, Betsy C Herold
Publicado em 2010-01-01

Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009).

Por Urvi M Parikh, Photini Kiepiela, Shayhana Ganesh, Kailazarid Gomez, Stephanie Horn, Krista Eskay, Cliff Kelly, Barbara Mensch, Pamina Gorbach, Lydia Soto-Torres, Gita Ramjee, John W Mellors, MTN-009 Protocol Team, IPTc Taskforce
Publicado em 2013-01-01

Socioecological factors influencing women’s HIV risk in the United States: qualitative findings from the women’s HIV SeroIncidence study (HPTN 064)

Por Paula M. Frew, Kimberly Parker, Linda Vo, Danielle Haley, Ann O’Leary, Dazon Dixon Diallo, Carol E. Golin, Irene Kuo, Lydia Soto-Torres, Jing Wang, Adaora A. Adimora, Laura A. Randall, Carlos del Rio, Sally Hodder, the HIV Prevention Trials Network 064 (HTPN) Study Team
Publicado em 2016-08-01

Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.

Por Thesla Palanee-Phillips, Katie Schwartz, Elizabeth R Brown, Vaneshree Govender, Nyaradzo Mgodi, Flavia Matovu Kiweewa, Gonasagrie Nair, Felix Mhlanga, Samantha Siva, Linda-Gail Bekker, Nitesha Jeenarain, Zakir Gaffoor, Francis Martinson, Bonus Makanani, Sarita Naidoo, Arendevi Pather, Jessica Phillip, Marla J Husnik, Ariane van der Straten, Lydia Soto-Torres, Jared Baeten
Publicado em 2015-01-01